Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma

8 clinical trials · Condition

Record	Firm	Date
Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma (NCT04850495)	Yazeed Sawalha	2021-11-16
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma (NCT04799275)	National Cancer Institute (NCI)	2021-05-20
Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma (NCT04257578)	University of Washington	2020-12-02
19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers (NCT04464200)	Memorial Sloan Kettering Cancer Center	2020-07-06
Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma (NCT03892044)	David Bond, MD	2019-11-05
Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma (NCT03704714)	Northwestern University	2018-11-20
Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma (NCT03321643)	National Cancer Institute (NCI)	2018-09-18
Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma (NCT03440567)	City of Hope Medical Center	2018-04-02

Every clearance here is in the API, with alerts when new ones post.